Navidea Biopharmaceuticals Announces The Presentation Of Lymphoseek® Data At Upcoming Scientific Meetings

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Lymphoseek ^® (technetium Tc 99m tilmanocept) studies in breast cancer and melanoma are being presented during the Radiological Society of North America Conference (RSNA) in Chicago and the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas. Details of the poster presentations are listed below.

Conference:			Radiological Society of North America Conference (RSNA)
Date:			November 25-30, 2012
Location:			Chicago
Poster Title 1:			In Phase 3 Clinical Studies in Melanoma and Breast Cancer, Receptor-Targeted (CD206) Tc 99m Tilmanocept Provided Enhanced Intraoperative Lymphatic Mapping, Leading to Increased Pathology Findings in Patients and Upstaging in Pathology-Positive Patient
Author:			Frederick Cope, Ph.D., Navidea Biopharmaceuticals
Session, Date:			Poster Sessions, Monday, Nov. 26, 2012, 12:15 – 12:45 p.m.
Poster Title 2:			A Phase 3 Clinical Trial Employing Tc 99m Tilmanocept, a Novel CD206-Targeted Intraoperative Lymphatic Mapping Agent For Breast Cancer and Melanoma, Shows Significant Concordance between Preoperative Imaging and Intraoperative Localization of Disease
Author:			Frederick Cope, Ph.D., Navidea Biopharmaceuticals
Session, Date:			Poster Sessions, Wednesday, Nov. 28, 2012, 12:45 – 1:15 p.m.
Conference:			CTRC-AACR San Antonio Breast Cancer Symposium
Date:			December 4-8, 2012
Location:			San Antonio, Texas
Poster Title:			Tc 99m Tilmanocept and Sulfur Colloid Injection: A comparison of Preoperative Imaging and Intraoperative Lymphatic Mapping of Breast Cancer Patients – Localization Rate and Degree of Localization
Author:			Frederick Cope, Ph.D., Navidea Biopharmaceuticals
Session, Date:			Poster Session 1, Wednesday, Dec. 5, 2012, 5 – 7 p.m.

About Lymphoseek ^®

Lymphoseek ^® (technetium Tc 99m tilmanocept) Injection is a novel, receptor-targeted, small-molecule, investigational radiopharmaceutical used in lymphatic mapping procedures that are performed to help stage cancers such as breast cancer and melanoma. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

Lymphatic mapping is a procedure in which lymph nodes that may contain tumor metastases are identified and biopsied to determine if cancer has spread beyond the primary tumor. Accurate staging of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. According to the American Cancer Society, approximately 229,000 new cases of breast cancer and 76,000 new cases of melanoma are expected to be diagnosed in the United States in 2012.

1 2 3 Next › Last »